Citigroup has recently initiated Denali Therapeutics Inc (DNLI) stock to Buy rating, as announced on December 13, 2023, according to Finviz. Earlier, on November 20, 2023, JP Morgan had resumed the stock to Overweight, setting a price target of $28. Cantor Fitzgerald also resumed Overweight rating with a price target of $35. Additionally, B. Riley Securities initiated Buy rating on September 6, 2023, with a target price of $38. SVB Securities analysts, in their report published on January 30, 2023, also initiated Outperform rating for Denali Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Denali Therapeutics Inc (DNLI) Stock Trading Recap
On Tuesday, Denali Therapeutics Inc (DNLI) stock saw a decline, ending the day at $28.67 which represents a decrease of $-0.46 or -1.58% from the prior close of $29.13. The stock opened at $29.18 and touched a low of $28.46 during the day, reaching a high of $29.67. The volume of shares traded was 0.79 million falling short of the average volume of 0.99 million.
DNLI Stock Performance and Moving Averages
In recent trading, Denali Therapeutics Inc (DNLI) stock price has shown some volatility, fluctuating -5.44% over the last five trades and 17.31% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 47.94%, and it has gained 31.88% in the previous three months. Currently, DNLI is trading at 0.66%, 12.26%, and 36.29% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, DNLI, a Healthcare sector stock, is trading -10.77% below its 52-week high but remains 96.91% above its 52-week low. The Average True Range (ATR) (14 days) of 1.11 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Denali Therapeutics Inc’s Profitability and Valuation Ratios
Denali Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -39085.40% and a profit margin of -33121.86%, with a gross margin of 47.94%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Denali Therapeutics Inc’s market capitalization stands at $4.10 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 3231.81, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 2.96, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 16.82% of Denali Therapeutics Inc (DNLI)’s shares, while financial institutions hold 84.19%.
Notable insider trades include Schuth Alexander O., COFO and Secretary at Denali Therapeutics Inc (DNLI), who sold 5806 shares on Aug 20 ’24, at $23.65 each, totaling $0.14 million. On Aug 21 ’24, Ho Carole, Chief Medical Officer, sold 20005 shares for $24.57 each, amounting to $0.49 million. Additionally, on Jul 01 ’24, Krognes Steve E. sold 30000 shares at $22.12 each, generating $0.66 million.
